Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors

US9416111B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Andrew M. Haidle · Cambridge, US
• Michael D. Altman · Cambridge, US
• Solomon D. Kattar · Arlington, US
• Matthew Christopher · Brookline, US
• John Michael Ellis · Needham, US
• Christian Fischer · Natick, US
• Alan B. Northrup · Reading, US
• Kaleen Konrad Childers · Medfield, US

Key dates

• Filing date: Jun 17, 2013
• Grant date: Aug 16, 2016
• Expiry date: Jun 17, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides certain substituted diazine and triazine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.